Bevacizumab Fails to Improve Survival in Resected High-Risk Melanoma
Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.
Tumor Location Prognostic for Outcomes Even After Multivariable Adjustment
The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.
Midostaurin Improves Survival in FLT3-Mutant AML
Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.
Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates
Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.
Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma
An anti–PD-1 monoclonal antibody is safe and effective for patients with unresectable, locally advanced, or metastatic cutaneous squamous cell carcinoma.
NSAID Use After Diagnosis Improved CRC Survival in KRAS Wild-Type Patients
Long-term survivors of wild-type KRAS colorectal cancer tumors had significantly improved survival with regular use of nonsteroidal anti-inflammatory drugs.
Nintedanib Combination Delayed Progression in Malignant Mesothelioma
Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.
SUNSHINE: High-Dose Vitamin D Improved PFS in Colorectal Cancer
This video highlights results of the SUNSHINE study, which found that high-dose vitamin D added to standard treatment slowed disease progression in newly diagnosed metastatic colorectal cancer.
ASCO 2017: Updates on HER2-Positive Breast Cancer Treatment
This video highlights the latest studies presented at the 2017 ASCO Annual Meeting on the treatment of HER2-positive breast cancer.
US Could Save Nearly $1 Billion With Pembrolizumab Dosing Change
This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.
Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition
This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.